Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. GOOGL
6. APGE
7. ABBV
8. USO
9. MSFT
10. IBM

Go back to Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress

Alnylam Pharma (ALNY) Tops Q4 EPS by 6c, Misses on Revenue; Offers FY26 Revenue Guidance

February 12, 2026 8:04 AM EST

Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of $1.25, $0.06 better than the analyst estimate of $1.19. Revenue for the quarter came in at $1.1 billion versus the consensus estimate of $1.15 billion.

GUIDANCE:

Alnylam Pharma sees FY2026 revenue of $4.9-5.3 billion, versus the consensus of... More